Literature DB >> 6249192

CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.

J A Retsema, A R English, A E Girard.   

Abstract

CP-45,899 is a new, semisynthetic beta-lactamase inhibitor. When tested alone, CP-45,899 displayed only weak antibacterial activity, with the notable exception of its potent action against penicillin-susceptible and -resistant Neisseria gonorrhoeae. A combination of 3.12 microgram of CP-45,899 per ml with 3.12 microgram of ampicillin per ml, tested in broth cultures, inhibited ca. 90% of resistant Staphylococcus and Haemophilus influenzae strains; similar data were obtained in a variety of media. The same combination of CP-45,899 with ampicillin or penicillin G inhibited 90% of Bacteroides fragilis as interpreted from agar dilution minimal inhibitory concentrations. Inhibitory concentrations of CP-45,899-ampicillin were bactericidal against H. influenzae strains and were as bactericidal as nafcillin or cephalothin against S. aureus. Ampicillin-resistant S. aureus, H. influenzae, and B. fragilis strains did not develop resistance to CP-45,899-ampicillin when transferred as many as six passages in the presence of a sublethal concentration of the combination.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6249192      PMCID: PMC283841          DOI: 10.1128/AAC.17.4.615

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Suppression of intrinsic resistance to methicillin and other penicillins in Staphylococcus aureus.

Authors:  L D Sabath; S J Wallace; D A Gerstein
Journal:  Antimicrob Agents Chemother       Date:  1972-11       Impact factor: 5.191

2.  CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.

Authors:  A R English; J A Retsema; A E Girard; J E Lynch; W E Barth
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

3.  Carbenicillin indanyl sodium, an orally active derivative of carbenicillin.

Authors:  A R English; J A Retsema; V A Ray; J E Lynch
Journal:  Antimicrob Agents Chemother       Date:  1972-03       Impact factor: 5.191

4.  Function of the outer membrane of Escherichia coli as a permeability barrier to beta-lactam antibiotics.

Authors:  W Zimmermann; A Rosselet
Journal:  Antimicrob Agents Chemother       Date:  1977-09       Impact factor: 5.191

5.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

6.  A new type of penicillin resistance of Staphylococcus aureus.

Authors:  L D Sabath; N Wheeler; M Laverdiere; D Blazevic; B J Wilkinson
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

  6 in total
  28 in total

1.  In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters.

Authors:  R J Fass; W W Gregory; R F D'Amato; J M Matsen; D N Wright; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  New sensitive bioassay for sulbactam in bovine tissues.

Authors:  G H Keeler; J P Stankewich; A E Girard; J J Rash
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

3.  Evaluation of in vitro methods for testing susceptibility of anaerobes to ampicillin-sulbactam and amoxicillin-clavulanic acid.

Authors:  P C Fuchs; A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948

4.  In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations.

Authors:  R N Jones
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Sulbactam/ampicillin versus cefotaxime as initial therapy in serious soft tissue, joint and bone infections.

Authors:  L Löffler; A Bauernfeind; W Keyl
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Side chain modifications in lankacidin group antibiotics.

Authors:  J W McFarland; D K Pirie; J A Retsema; A R English
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

Review 7.  Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H A Friedel; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

8.  Evaluation of three 4"-deoxy-4"-sulfonamido-oleandomycin derivatives with erythromycin-like antibacterial potency.

Authors:  A R English; J A Retsema; A E Girard; W Schelkly; J E Lynch
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

9.  Antibacterial activity and kill kinetics of ampicillin/sulbactam (CP-45899) combinations against Escherichia coli and Klebsiella aerogenes.

Authors:  J E Fuglesang; T Bergan
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

10.  Pharmacokinetics of sultamicillin in mice, rats, and dogs.

Authors:  A R English; D Girard; S L Haskell
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.